Duopharma, Introduces Its Second Oncology Drug to Treat Chronic Myeloid Leukemia
Highlights: Duopharma HAPI Sdn Bhd, a subsidiary of Malaysia’s Duopharma, has introduced its second oncology drug to treat chronic myeloid leukemia at its plant in Shah Alam. The new drug is a significant addition to the company’s growing portfolio of halal-certified pharmaceutical products and demonstrates its commitment to developing safe and effective treatments for patients with cancer. The launch of the new oncology drug further cements Duopharma’s position as a leader in the halal pharmaceutical space and highlights the increasing demand for halal-certified medications in Malaysia and beyond.
Link to Original Article